|[February 19, 2013]
Research and Markets: Orphan Drugs Partnering Terms and Agreements
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/4j7npr/orphan_drugs)
has announced the addition of the "Orphan
Drugs Partnering Terms and Agreements" report to their offering.
The Orphan Drugs Partnering Agreements report provides an understanding
and access to the orphan drugs partnering deals and agreements entered
into by the worlds leading healthcare companies.
- Trends in orphan drugs partnering deals
- Disclosed headlines, upfronts, milestones and royalties by stage of
- Orphan drugs partnering contract documents
- Top orphan drugs deals by value
The OrphanDrugs Partnering Terms and Agreements report provides an
understanding and access to the orphan drugs partnering deals and
agreements entered into by the worlds leading healthcare companies.
The report provides an understanding and analysis of how and why
companies enter orphan drugs partnering deals. The majority of deals are
discovery or development stage whereby the licensee obtains a right or
an option right to license the licensors orphan drugs technology. These
deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes.
Understanding the flexiblity of a prospective partner's negotiated
deals terms provides critical insight into the negotiation process in
terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments
clauses, the devil is in the detail in terms of how payments are
triggered - contract documents provide this insight where press releases
This report contains over 500 links to online copies of actual orphan
drugs deals and where available, contract documents as submitted to the
Securities Exchange Commission by companies and their partners. Contract
documents provide the answers to numerous questions about a prospective
partner's flexibility on a wide range of important issues, many of which
will have a significant impact on each party's ability to derive value
from the deal.
The initial chapters of this report provide an orientation of orphan
drugs dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst chapter 2
provides an overview of the trends in orphan drugs dealmaking since
2007, including details of disclosed headline, upfront, milestone and
Chapter 3 provides a review of the leading orphan drugs deals since
2007. Deals are listed by headline value. Where the deal has an
agreement contract published at the SEC (News - Alert) a link provides online access to
Chapter 4 provides a comprehensive and detailed review of orphan drugs
partnering deals signed and announced since 2007, and where available, a
contract document is available in the public domain. The chapter is
organized by company A-Z, stage of development at signing, deal type
(collaborative R&D, co-promotion, licensing etc), and specific oncology
therapy focus. Each deal title links via Weblink to an online version of
the deal record and where available, the contract document, providing
easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in orphan drugs partnering and dealmaking since
In conclusion, this report provides everything a prospective dealmaker
needs to know about partnering in the research, development and
commercialization of orphan drugs technologies and products.
Key Topics Covered:
Chapter 1 - Introduction
Chapter 2 - Trends in orphan drugs dealmaking
Chapter 3 - Leading Orphan Drugs deals
Chapter 4 - Orphan Drugs dealmaking directory
Chapter 5 -Partnering resource center
For more information visit http://www.researchandmarkets.com/research/4j7npr/orphan_drugs
[ Back To Technology News's Homepage ]